Globus Medical shares fell over 22% after the company missed Q1 expectations and lowered its EPS outlook. Revenue declined 1.4% to $598.1M, with adjusted EPS at 68¢—6¢ below Wall Street estimates.
The shortfall was linked to early Nevro integration, supply chain disruptions, and delayed Enabling Technology deals. Despite this, Globus reaffirmed its $2.8B–$2.9B revenue forecast but lowered EPS guidance to $3.00–$3.30.
Truist and Needham analysts remain cautious, while BTIG sees sub-$60 valuation as an opportunity.
Follow MEDWIRE.AI for surgical tech and MedTech earnings updates.
